Ahpra registration PHY0002298174
How these guides are written and reviewed →
Some conditions, especially cancer, cause fluid to build up repeatedly around the lung, making breathing difficult. Draining it helps, but it usually comes back. There are two main long-term solutions: sticking the lung to the chest wall so fluid has nowhere to collect, or leaving a small permanent tube in place so fluid can be drained at home. This page explains both, and when each is chosen.
The problem
A malignant pleural effusion is a marker of advanced disease and a major cause of breathlessness. Simple aspiration relieves symptoms but the fluid reaccumulates, often within days. The clinical question is therefore not how to drain it once, but how to stop it dominating whatever time the patient has — which makes this as much a palliative decision as a procedural one.
Two definitive options exist, and they work in opposite ways.
Pleurodesis
Pleurodesis deliberately obliterates the pleural space by inducing inflammation so the visceral and parietal pleura adhere. Talc is the most effective agent, delivered either as a slurry through a chest drain or insufflated at thoracoscopy (poudrage).
The TAPPS trial randomised talc poudrage against talc slurry and found no difference in pleurodesis failure at 90 days, which simplified practice considerably — the more invasive thoracoscopic route is not required for the pleurodesis itself.1
Pleurodesis requires one condition absolutely: the lung must be able to re-expand and contact the chest wall. If it cannot, the surfaces never appose and the procedure fails.
The trapped or non-expandable lung
When tumour, fibrous peel or endobronchial obstruction prevents the lung from expanding, the space fills with fluid or air because the lung physically cannot fill it. Deep breathing, incentive spirometry, positive pressure and manual techniques will not change this, and persisting with them wastes the patient's limited energy. Recognising a trapped lung is the useful contribution — it changes the management plan from pleurodesis to an indwelling catheter.
Clues include a persistent pneumothorax-like space after drainage, chest pain during drainage, failure of the lung to expand on post-drainage imaging, and highly negative pleural pressures during aspiration.
Indwelling pleural catheters
An IPC is a small tunnelled catheter left in place long-term, allowing the patient or a carer to drain fluid at home into vacuum bottles. It does not require the lung to expand, which is why it is the answer to the trapped lung. In a proportion of patients, repeated drainage produces spontaneous pleurodesis and the catheter can eventually be removed.
| Trial | Comparison | Result |
|---|---|---|
| TIME22 | IPC vs chest tube and talc pleurodesis | Similar breathlessness relief; fewer inpatient days with IPC; more adverse events with IPC |
| AMPLE3 | IPC vs talc pleurodesis | Fewer total hospital days with IPC over the remaining lifespan; comparable symptom control |
| IPC-PLUS4 | IPC plus talc vs IPC alone | Talc through an existing IPC substantially increases pleurodesis success without extra hospitalisation |
| TAPPS1 | Talc poudrage vs talc slurry | No difference in failure rate at 90 days |
Current British Thoracic Society and ATS/STS/STR guidance treats IPC and pleurodesis as reasonable alternatives for the expandable lung, decided with the patient on the basis of what matters to them — hospital time versus catheter care — and mandates IPC where the lung is non-expandable.5,6
What this means at the bedside
Living with an IPC
- Mobilisation is unrestricted and should be actively encouraged. The catheter is tunnelled and secure; patients walk, exercise and go home with it.
- Drainage regimens vary — typically symptom-guided or a set schedule. Draining large volumes rapidly can cause chest pain or cough; slowing or stopping is the correct response.
- Showering is permitted with an appropriate dressing; swimming and baths are not.
- Report cellulitis, increasing pain, fever, or a sudden change in drainage volume or character. Pleural infection is the main serious complication.
- Loculation presents as falling drainage with unchanged or worsening breathlessness — not a physiotherapy problem.
After pleurodesis
- Pain during and after instillation is expected and needs pre-emptive analgesia.
- Fever in the first 24–48 hours is a common inflammatory response rather than infection.
- Patient rotation is not required. Talc distributes adequately without it, and rotation protocols have been abandoned in most units.
- Mobilisation is encouraged from the outset; the drain is not a reason to stay in bed. See Chest Drains.
The physiotherapy contribution
The instinct to "treat the chest" is misplaced here. This is fluid in a space, not secretions in an airway, and there is no clearance problem to solve. The valuable contributions are different:
- Breathlessness management — positioning, breathing control, the handheld fan, pacing and energy conservation. This is the core intervention and it is genuinely effective. See Breathing Retraining and Breathlessness.
- Recognising what will not respond. A dull base with absent breath sounds is fluid; escalating a clearance technique against it achieves nothing.
- Maintaining function in a population with advanced malignancy — mobility, transfers, stairs, and the equipment to keep someone at home.
- Rehabilitation alongside palliative care, which is not a contradiction. Function and symptom control matter more, not less, as prognosis shortens.
Non-malignant recurrent effusions — hepatic hydrothorax, refractory heart failure — are increasingly managed with IPCs too, and the same principles apply.
Role of the physiotherapist
Know which procedure the patient has had and why, because it tells you whether the lung is expandable. Treat breathlessness rather than the effusion. Mobilise freely with an IPC in situ. Escalate signs of pleural infection. And be the clinician who recognises that a trapped lung needs a different plan rather than a harder-working technique.
Evidence summary
Framing. Malignant pleural effusion management has shifted decisively over the last decade from an inpatient, pleurodesis-first model to an ambulatory, catheter-capable model in which the primary outcome is time spent out of hospital rather than radiographic success.3,5,6 The relevant physiotherapy skill set has shifted with it — from ward-based chest treatment towards breathlessness intervention and functional maintenance in the community.
Evidence — pleurodesis versus IPCTIME2 established equivalent breathlessness relief with fewer inpatient days for IPC, at the cost of more adverse events.2 AMPLE confirmed the reduction in total hospitalisation across the remaining lifespan.3 IPC-PLUS showed that talc instilled through an existing catheter markedly improves pleurodesis rates without additional admission, effectively combining the two strategies.4 TAPPS removed the argument for routine thoracoscopic poudrage over bedside slurry.1
Physiotherapy implicationsThere is no airway clearance indication in an uncomplicated effusion, and no volume-recruitment technique will overcome a non-expandable lung. The evidence-based contributions are breathlessness management, mobility maintenance, and the recognition of complications — pleural infection, loculation, and catheter-site problems. Mobilisation with an IPC should be explicitly encouraged rather than tacitly permitted; unnecessary caution is a common source of avoidable deconditioning.
Evidence gapsNo trial has evaluated a structured physiotherapy or breathlessness-service intervention specifically in the IPC population, despite it being a large, symptomatic and largely ambulatory group. Optimal drainage frequency remains uncertain. The role of exercise rehabilitation in malignant pleural disease is essentially unstudied.
References & evidence base
- Bhatnagar R, Piotrowska HEG, Laskawiec-Szkonter M, et al. Effect of thoracoscopic talc poudrage vs talc slurry via chest tube on pleurodesis failure rate among patients with malignant pleural effusions (TAPPS): a randomized clinical trial. JAMA 2020;323(1):60–69.
- Davies HE, Mishra EK, Kahan BC, et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion (TIME2): a randomized controlled trial. JAMA 2012;307(22):2383–2389.
- Thomas R, Fysh ETH, Smith NA, et al. Effect of an indwelling pleural catheter vs talc pleurodesis on hospitalization days in patients with malignant pleural effusion (AMPLE): a randomized clinical trial. JAMA 2017;318(19):1903–1912.
- Bhatnagar R, Keenan EK, Morley AJ, et al. Outpatient talc administration by indwelling pleural catheter for malignant effusion (IPC-PLUS). N Engl J Med 2018;378(14):1313–1322.
- Roberts ME, Rahman NM, Maskell NA, et al. British Thoracic Society guideline for pleural disease. Thorax 2023;78(Suppl 3):s1–s42.
- Feller-Kopman DJ, Reddy CB, DeCamp MM, et al. Management of malignant pleural effusions. An official ATS/STS/STR clinical practice guideline. Am J Respir Crit Care Med 2018;198(7):839–849.
References are numbered in citation order (Vancouver/BMJ style) and were current at the time of writing. Guidelines are living documents — verify against the latest version before clinical use.
Physiotherapy around major chest, cardiac and upper abdominal procedures — from open surgery to bronchoscopic, catheter-based and bedside treatments — aims to reduce chest complications and shorten the return to normal function.
Corrections: If something on this page is wrong, out of date or unclear, we want to know. Email reception@inspireclinic.au with the page name and what you believe is incorrect. Substantive corrections are made promptly, and the guide’s version and last-updated date are changed to reflect it.